Find a Cancer Clinical Trial for Your Child
Memorial Sloan Kettering conducts hundreds of clinical trials to improve care for people with many types of cancer. This includes more than 100 studies for children, teens, and young adults. Use this tool to browse our list of open clinical trials for young people. Each listing explains the purpose of the trial, who is eligible, and how to get more information.
New clinical trials are always opening. For more information and to find out about our latest studies, call 833-675-5437 or email us at [email protected].
-
Inotuzumab ozogamicin is a drug used to treat adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite prior therapy. In this study, researchers are evaluating its use in children and young adults with recurrent or persistent B-cell ALL.
-
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
- A Phase 2 Study of Reduced Chemotherapy and Antibody-Based Therapy in Children With Neuroblastoma
Full Title N10: Reduced Therapy for High-Risk Neuroblastoma
Purpose
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
The drug combination is called N10 and includes various chemotherapy drugs that are very effective at killing neuroblastoma. N10 also includes immunotherapy: treatment with agent called naxitamab. This drug is a monoclonal antibody that gets the child’s own white blood cells to kill neuroblastoma.
The number of different drugs in N10 may make it less likely that the cancer will become resistant to chemotherapy. Researchers also think that N10 may have fewer side effects on the body than the usual treatment for high-risk neuroblastoma. Examples of these side effects include hearing problems and effects on major organs, such as the heart.
If your child joins this study, they will get 3 different combinations of chemotherapy drugs given at different times:
- Cycles 1 and 4: Cyclophosphamide, topotecan, and vincristine
- Cycle 2: Ifosfamide, carboplatin, and etoposide
- Cycle 3: Cyclophosphamide, doxorubicin, and vincristine
After cycle 3, your child will have some stem cells removed (blood-forming cells) as part of their usual care. They will also have surgery to remove the tumor.
After cycle 4, they will have 2 cycles of treatments that include naxitamab and GM-CSF. GM-CSF makes white blood cells better killers of neuroblastoma. Between these 2 cycles, they will have radiation therapy. Your child’s doctor might give other medications as well, depending on how well your child’s cancer responds to the treatment.
Who Can Join
To join this study, there are a few conditions. Your child must:
- Have high-risk neuroblastoma that has not been treated with more than 1 cycle of chemotherapy.
- Be under age 19 years.
Contact
For more information and to see if your child can join this study, please call 833-MSK-KIDS (833-675-5437).
Protocol
24-144Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06528496ClinicalTrials.gov
-
The purpose of this study is to assess the safety and effectiveness of combining a "bivalent" vaccine with two agents that stimulate the immune system: a sugar called beta-glucan and a medication called GM-CSF. The treatment is designed to prevent the relapse of patients with high-risk neuroblastoma that is in complete remission. This bivalent vaccine works by stimulating an immune response against two different antigens, which are markers on the surface of a cell.
-
Severe aplastic anemia is a serious condition where the bone marrow does not make the normal amount of blood cells. Bone marrow transplantation is one way to treat this disease. It has been reserved for people under age 40 with a related donor whose cells fully match theirs. However, advances have been made in bone marrow transplantation that make it an option for more people.
-
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
-
PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).
-
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
-
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.